NOSH-Aspirin is a category of new hybrids of aspirin, bearing both nitric oxide (NO)- and hydrogen sulfide (H2S)- releasing areas. Preliminary studies have found that four NOSH variants, evaluated in eleven different human cancer cell lines, were effective in inhibiting the growth of these cell lines. NOSH-1 was also devoid of any cellular toxicity, and was comparable to aspirin in its anti-inflammatory properties.[1][2]
References edit
- ^ Chattopadhyay M, Kodela R, Olson KR, Kashfi K (March 2012). "NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model". Biochem. Biophys. Res. Commun. 419 (3): 523–8. doi:10.1016/j.bbrc.2012.02.051. PMID 22366248.
- ^ Kodela, Ravinder; Chattopadhyay, Mitali; Kashfi, Khosrow (8 March 2012). "NOSH-Aspirin: A Novel Nitric Oxide–Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals". ACS Medicinal Chemistry Letters. 3 (3): 257–262. doi:10.1021/ml300002m. PMC 3423220. PMID 22916316.
 | This oncology article is a stub. You can help Wikipedia by expanding it. |